These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 33742977)

  • 1. Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies.
    Suárez C; Díaz-Mejía N; Morales-Barrera R; González M; Mateo J; Carles J
    Curr Opin Urol; 2021 May; 31(3):242-248. PubMed ID: 33742977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
    Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
    Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy.
    Urman D; Deshler L; Weise N; Shabaik A; Derweesh I; Bagrodia A; Rose B; Herchenhorn D; McKay RR
    Clin Genitourin Cancer; 2023 Dec; 21(6):660-668.e1. PubMed ID: 37858374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma.
    Patel HV; Srivastava A; Srinivasan R; Singer EA
    Curr Opin Oncol; 2021 May; 33(3):212-220. PubMed ID: 33818540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future strategies in nonclear-cell metastatic renal cell carcinoma.
    Albiges L; Escudier B
    Curr Opin Urol; 2015 Sep; 25(5):367-73. PubMed ID: 26153638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
    Bukowski RM
    Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
    Tannir NM; Jonasch E; Albiges L; Altinmakas E; Ng CS; Matin SF; Wang X; Qiao W; Dubauskas Lim Z; Tamboli P; Rao P; Sircar K; Karam JA; McDermott DF; Wood CG; Choueiri TK
    Eur Urol; 2016 May; 69(5):866-74. PubMed ID: 26626617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.
    Puente J; García Del Muro X; Pinto Á; Láinez N; Esteban E; Arranz JÁ; Gallardo E; Méndez MJ; Maroto P; Grande E; Suárez C
    Target Oncol; 2016 Apr; 11(2):129-41. PubMed ID: 26706236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges?
    Mir MC; Albiges L; Bex A; Hora M; Giannarini G; Volpe A; Rouprêt M;
    Eur Urol Oncol; 2021 Oct; 4(5):843-850. PubMed ID: 32553707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Borchiellini D
    Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving therapeutic targets in renal cell carcinoma.
    Singer EA; Gupta GN; Marchalik D; Srinivasan R
    Curr Opin Oncol; 2013 May; 25(3):273-80. PubMed ID: 23455028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study).
    Rodriguez-Vida A; Bamias A; Esteban E; Saez MI; Lopez-Brea M; Castellano D; Caballero C; Gonzalez-Larriba JL; Calvo E; Macia S; Ravaud A; Bellmunt J
    BJU Int; 2020 Nov; 126(5):559-567. PubMed ID: 32654362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment approaches in renal cell carcinoma.
    Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
    Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.
    Kanesvaran R; Watt K; Turnbull JD; Armstrong AJ; Wolkowiez MC; George DJ
    Clin Genitourin Cancer; 2015 Aug; 13(4):319-327. PubMed ID: 26174223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region.
    So TH; Sharma S; Parij R; Spiteri C; Chawla E; Pandey P; Rajasekaran T
    Expert Rev Anticancer Ther; 2023; 23(8):853-863. PubMed ID: 37458169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.
    Agarwala SS; Case S
    Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.